Haggai Hermesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haggai Hermesh has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Weizman
Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University
9 shared publications H Munitz
7 shared publicationsD Aizenberg
4 shared publicationsRoni Shiloh
4 shared publicationsHanan Munitz
3 shared publicationsIris Manor
3 shared publications
Latest Publications
- 1 November 2020
- Published by Elsevier in Psychiatry Research
- Vol. 293, 113356
Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study
- 1 November 2020
- Published by Elsevier in Psychiatry Research
- Vol. 293, 113356
Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S392
P.2.b.014 The use of smartphone app for early detection of manic or depressive episodes in affective patients
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S392
P.2.b.014 The use of smartphone app for early detection of manic or depressive episodes in affective patients
- 19 September 2014
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 42 (2) , 90-97
Bruxism and oral parafunctional hyperactivity in social phobia outpatients
Anxiety and selective serotonin reuptake inhibitors (SSRIs) are considered aggravating factors for bruxism. We examined the influence of anxiety, depression and SSRI on bruxism in social phobia (SP). Twenty-three drug naïve, 17 SSRI-treated SP patients and 33 healthy controls underwent a psychiatric assessment and completed Leibowitz Social Anxiety Scale and Beck Depression Inventory. Oral parafunctional activity (PF) was evaluated by TM-dental examination and by a questionnaire. Drug- naïve and SSRI-treated SP patients did not differ on demographic and clinical measures. Awake bruxism, 'JAW PLAY' and at least one PF were more prevalent in SP than in controls. Severity of SP predicted the presence of PF. SP, but not depression, was associated with higher risk of oral PF and awake bruxism. Chronic SSRI treatment of SP did not affect sleep and awake bruxism. Dental and anxiety screening may improve the prognosis psychiatric and dental patients. Effective treatment of SP may mitigate bruxism.
- 19 September 2014
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 42 (2) , 90-97
Bruxism and oral parafunctional hyperactivity in social phobia outpatients
Anxiety and selective serotonin reuptake inhibitors (SSRIs) are considered aggravating factors for bruxism. We examined the influence of anxiety, depression and SSRI on bruxism in social phobia (SP). Twenty-three drug naïve, 17 SSRI-treated SP patients and 33 healthy controls underwent a psychiatric assessment and completed Leibowitz Social Anxiety Scale and Beck Depression Inventory. Oral parafunctional activity (PF) was evaluated by TM-dental examination and by a questionnaire. Drug- naïve and SSRI-treated SP patients did not differ on demographic and clinical measures. Awake bruxism, 'JAW PLAY' and at least one PF were more prevalent in SP than in controls. Severity of SP predicted the presence of PF. SP, but not depression, was associated with higher risk of oral PF and awake bruxism. Chronic SSRI treatment of SP did not affect sleep and awake bruxism. Dental and anxiety screening may improve the prognosis psychiatric and dental patients. Effective treatment of SP may mitigate bruxism.
- 1 September 2002
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 41 (9) , 1045-1053
Serum Creatine Kinase Levels in Untreated Hospitalized Adolescents During Acute Psychosis
- 1 September 2002
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 41 (9) , 1045-1053
Serum Creatine Kinase Levels in Untreated Hospitalized Adolescents During Acute Psychosis
- 1 June 2002
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (3) , 252-256
High Serum Creatinine Kinase Level: Possible Risk Factor for Neuroleptic Malignant Syndrome
High creatinine kinase (CK) levels and leukocytosis are known to be associated with neuroleptic malignant syndrome (NMS). The authors sought to determine if their presence during non-NMS psychotic episodes is predictive of the later development of NMS. Sixteen psychotic inpatients who met the criteria for NMS were included. For statistical comparison, two control groups were formed by matching each study patient with two non-NMS patients for age, gender, ethnicity, and year and ward of hospitalization (n = 32). The maximal individual serum levels of CK, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT), and white blood cell count (WBC) during all non-NMS psychotic episodes (Brief Psychiatric Rating Scale 40) were averaged. To normalize the distribution, the individual averages were transformed to natural logarithms (Ln). Mean Ln (average [CK]) in the patients with NMS was found to be 6.46 ± 0.91 IU/L, and in the non-NMS patients, 5.24 ± 0.90 IU/L (actual serum CK levels, 911 ± 747 IU/L and 343 ± 620 IU/L, respectively). This difference was statistically significant (F [2,15] = 10.5, p < 0.0001). In addition, CK levels above the upper limit of normal were noted in 76% of psychotic episodes in the patients with NMS and in only 30% of psychotic episodes in the non-NMS patients (p < 0.0001). There was no significant difference between the NMS and non-NMS groups in Ln(LDH), Ln(SGOT), or Ln(WBC) (F [2,15] = 1.4, 2.1, and 0.9, respectively). The authors concluded that high serum CK level during non-NMS psychotic episodes seems to be a risk factor for future NMS. Therefore, CK measurement may be justified on admission of acutely psychotic patients who have other risk factors and a history of psychosis-associated CKemia.
- 1 June 2002
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (3) , 252-256
High Serum Creatinine Kinase Level: Possible Risk Factor for Neuroleptic Malignant Syndrome
High creatinine kinase (CK) levels and leukocytosis are known to be associated with neuroleptic malignant syndrome (NMS). The authors sought to determine if their presence during non-NMS psychotic episodes is predictive of the later development of NMS. Sixteen psychotic inpatients who met the criteria for NMS were included. For statistical comparison, two control groups were formed by matching each study patient with two non-NMS patients for age, gender, ethnicity, and year and ward of hospitalization (n = 32). The maximal individual serum levels of CK, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT), and white blood cell count (WBC) during all non-NMS psychotic episodes (Brief Psychiatric Rating Scale 40) were averaged. To normalize the distribution, the individual averages were transformed to natural logarithms (Ln). Mean Ln (average [CK]) in the patients with NMS was found to be 6.46 ± 0.91 IU/L, and in the non-NMS patients, 5.24 ± 0.90 IU/L (actual serum CK levels, 911 ± 747 IU/L and 343 ± 620 IU/L, respectively). This difference was statistically significant (F [2,15] = 10.5, p < 0.0001). In addition, CK levels above the upper limit of normal were noted in 76% of psychotic episodes in the patients with NMS and in only 30% of psychotic episodes in the non-NMS patients (p < 0.0001). There was no significant difference between the NMS and non-NMS groups in Ln(LDH), Ln(SGOT), or Ln(WBC) (F [2,15] = 1.4, 2.1, and 0.9, respectively). The authors concluded that high serum CK level during non-NMS psychotic episodes seems to be a risk factor for future NMS. Therefore, CK measurement may be justified on admission of acutely psychotic patients who have other risk factors and a history of psychosis-associated CKemia.
- 1 April 2001
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 11 (2) , 111-115
Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level
- 1 April 2001
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 11 (2) , 111-115
Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level
- 1 August 2000
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 157 (8) , 1327-1329
Heat Intolerance in Patients With Chronic Schizophrenia Maintained With Antipsychotic Drugs
Schizophrenia may be associated with hyperthermic syndromes such as febrile catatonia, neuroleptic malignant syndrome, and heatstroke. The authors hypothesized that an exercise-heat tolerance test would disclose abnormal thermoregulation in schizophrenic patients. Seven male schizophrenic outpatients in remission maintained on depot antipsychotic treatment and eight healthy comparison subjects completed a heat tolerance test that consisted of two 50-minute bouts of walking a motor-driven treadmill at 40xC (relative humidity=40%). A significantly higher rise in rectal and skin temperatures was observed in the patient group. No differences in heart rate, blood pressure, or perspiration were detected. Schizophrenic patients maintained on antipsychotic drugs exhibit impaired heat tolerance. Possible explanations are a reduced ability to convey heat from the body's core to the periphery with or without excessive heat production. The hyperthermic response to the heat tolerance test may reflect a dysfunction associated with schizophrenia, a neuroleptic-induced side effect, or both.
- 1 August 2000
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 157 (8) , 1327-1329
Heat Intolerance in Patients With Chronic Schizophrenia Maintained With Antipsychotic Drugs
Schizophrenia may be associated with hyperthermic syndromes such as febrile catatonia, neuroleptic malignant syndrome, and heatstroke. The authors hypothesized that an exercise-heat tolerance test would disclose abnormal thermoregulation in schizophrenic patients. Seven male schizophrenic outpatients in remission maintained on depot antipsychotic treatment and eight healthy comparison subjects completed a heat tolerance test that consisted of two 50-minute bouts of walking a motor-driven treadmill at 40xC (relative humidity=40%). A significantly higher rise in rectal and skin temperatures was observed in the patient group. No differences in heart rate, blood pressure, or perspiration were detected. Schizophrenic patients maintained on antipsychotic drugs exhibit impaired heat tolerance. Possible explanations are a reduced ability to convey heat from the body's core to the periphery with or without excessive heat production. The hyperthermic response to the heat tolerance test may reflect a dysfunction associated with schizophrenia, a neuroleptic-induced side effect, or both.
- 15 April 1999
- Vol. 136 (8) , 639-41
[Elevated serum levels of creatine kinase in acute psychotic patients].
- 15 April 1999
- Vol. 136 (8) , 639-41
[Elevated serum levels of creatine kinase in acute psychotic patients].
- 1 September 1998
- Published by Elsevier in Schizophrenia Research
- Vol. 33 (1-2) , 119-122
Bone age in adolescents with schizophrenia and obsessive-compulsive disorder
- 1 September 1998
- Published by Elsevier in Schizophrenia Research
- Vol. 33 (1-2) , 119-122
Bone age in adolescents with schizophrenia and obsessive-compulsive disorder
- 9 June 1998
- Vol. 21 (3) , 201-2
Alprazolam withdrawal delirium: a case report.
Benzodiazepine withdrawal delirium is thought to be uncommon. Only two clear reports of alprazolam withdrawal appear in the literature, but the use of this drug is expected to increase because of its recent approval for the treatment of panic disorder. We report on a patient with severe alprazolam withdrawal delirium that developed immediately after an accidental reduction of the dose. This case demonstrates importance of clinician awareness of the previous use of alprazolam in individual patients, especially in hospital settings where free patient use of drugs is prohibited.
- 9 June 1998
- Vol. 21 (3) , 201-2
Alprazolam withdrawal delirium: a case report.
Benzodiazepine withdrawal delirium is thought to be uncommon. Only two clear reports of alprazolam withdrawal appear in the literature, but the use of this drug is expected to increase because of its recent approval for the treatment of panic disorder. We report on a patient with severe alprazolam withdrawal delirium that developed immediately after an accidental reduction of the dose. This case demonstrates importance of clinician awareness of the previous use of alprazolam in individual patients, especially in hospital settings where free patient use of drugs is prohibited.